395 related articles for article (PubMed ID: 36457998)
21. LncRNA AFAP1-AS1 promotes tumorigenesis and epithelial-mesenchymal transition of osteosarcoma through RhoC/ROCK1/p38MAPK/Twist1 signaling pathway.
Shi D; Wu F; Mu S; Hu B; Zhong B; Gao F; Qing X; Liu J; Zhang Z; Shao Z
J Exp Clin Cancer Res; 2019 Aug; 38(1):375. PubMed ID: 31443665
[TBL] [Abstract][Full Text] [Related]
22. Pan-cancer analysis shows that IBSP is a potential prognostic and immunotherapeutic biomarker for multiple cancer types including osteosarcoma.
Pan B; Cheng X; Tan W; Liu R; Wu X; He J; Fan Q; Zhang Y; Cheng J; Deng Y
Front Immunol; 2023; 14():1188256. PubMed ID: 37457709
[TBL] [Abstract][Full Text] [Related]
23. An Ex Vivo 3D Tumor Microenvironment-Mimicry Culture to Study TAM Modulation of Cancer Immunotherapy.
Li YR; Yu Y; Kramer A; Hon R; Wilson M; Brown J; Yang L
Cells; 2022 May; 11(9):. PubMed ID: 35563889
[TBL] [Abstract][Full Text] [Related]
24. Mediator of RNA polymerase II transcription subunit 19 promotes osteosarcoma growth and metastasis and associates with prognosis.
Yu W; Zhang Z; Min D; Yang Q; Du X; Tang L; Lin F; Sun Y; Zhao H; Zheng S; He A; Li H; Yao Y; Shen Z
Eur J Cancer; 2014 Apr; 50(6):1125-36. PubMed ID: 24565852
[TBL] [Abstract][Full Text] [Related]
25. Long Noncoding RNA SNHG7 Promotes the Tumor Growth and Epithelial-to-Mesenchymal Transition via Regulation of miR-34a Signals in Osteosarcoma.
Deng Y; Zhao F; Zhang Z; Sun F; Wang M
Cancer Biother Radiopharm; 2018 Nov; 33(9):365-372. PubMed ID: 29989838
[TBL] [Abstract][Full Text] [Related]
26. Immunotherapy for osteosarcoma: Fundamental mechanism, rationale, and recent breakthroughs.
Chen C; Xie L; Ren T; Huang Y; Xu J; Guo W
Cancer Lett; 2021 Mar; 500():1-10. PubMed ID: 33359211
[TBL] [Abstract][Full Text] [Related]
27. Immune contexture of paediatric cancers.
Thakur MD; Franz CJ; Brennan L; Brouwer-Visser J; Tam R; Korski K; Koeppen H; Ziai J; Babitzki G; Ranchere-Vince D; Vasiljevic A; Dijoud F; Marec-Bérard P; Rochet I; Cannarile MA; Marabelle A
Eur J Cancer; 2022 Jul; 170():179-193. PubMed ID: 35660252
[TBL] [Abstract][Full Text] [Related]
28.
Luo Y; Tao H; Jin L; Xiang W; Guo W
Cancer Biother Radiopharm; 2020 Feb; 35(1):58-65. PubMed ID: 31724892
[No Abstract] [Full Text] [Related]
29. Tumor-associated macrophages in osteosarcoma.
Zhao Y; Zhang B; Zhang Q; Ma X; Feng H
J Zhejiang Univ Sci B; 2021 Nov; 22(11):885-892. PubMed ID: 34783219
[TBL] [Abstract][Full Text] [Related]
30. Engineering Nanoparticles for Targeted Remodeling of the Tumor Microenvironment to Improve Cancer Immunotherapy.
Gao S; Yang D; Fang Y; Lin X; Jin X; Wang Q; Wang X; Ke L; Shi K
Theranostics; 2019; 9(1):126-151. PubMed ID: 30662558
[TBL] [Abstract][Full Text] [Related]
31. Dysregulation of macrophage polarization is associated with the metastatic process in osteosarcoma.
Dumars C; Ngyuen JM; Gaultier A; Lanel R; Corradini N; Gouin F; Heymann D; Heymann MF
Oncotarget; 2016 Nov; 7(48):78343-78354. PubMed ID: 27823976
[TBL] [Abstract][Full Text] [Related]
32. Long Noncoding RNA FER1L4 Suppresses Tumorigenesis by Regulating the Expression of PTEN Targeting miR-18a-5p in Osteosarcoma.
Fei D; Zhang X; Liu J; Tan L; Xing J; Zhao D; Zhang Y
Cell Physiol Biochem; 2018; 51(3):1364-1375. PubMed ID: 30481787
[TBL] [Abstract][Full Text] [Related]
33. lncRNA‑CASC15 promotes osteosarcoma proliferation and metastasis by regulating epithelial‑mesenchymal transition via the Wnt/β‑catenin signaling pathway.
Wang H; Zhang P
Oncol Rep; 2021 May; 45(5):. PubMed ID: 33760218
[TBL] [Abstract][Full Text] [Related]
34. MicroRNAs Implications in the Onset, Diagnosis, and Prognosis of Osteosarcoma.
Ebrahimi N; Aslani S; Babaie F; Hemmatzadeh M; Pourmoghadam Z; Azizi G; Jadidi-Niaragh F; Mohammadi H
Curr Mol Med; 2021; 21(7):573-588. PubMed ID: 33272173
[TBL] [Abstract][Full Text] [Related]
35. Downregulated Long Non-Coding RNA MSC-AS1 Inhibits Osteosarcoma Progression and Increases Sensitivity to Cisplatin by Binding to MicroRNA-142.
Zhang L; Zhao G; Ji S; Yuan Q; Zhou H
Med Sci Monit; 2020 Mar; 26():e921594. PubMed ID: 32155139
[TBL] [Abstract][Full Text] [Related]
36. Metabolism and senescence in the immune microenvironment of osteosarcoma: focus on new therapeutic strategies.
Ying H; Li ZQ; Li MP; Liu WC
Front Endocrinol (Lausanne); 2023; 14():1217669. PubMed ID: 37497349
[TBL] [Abstract][Full Text] [Related]
37. Long non‑coding RNA GHET1 promotes osteosarcoma development and progression via Wnt/β‑catenin signaling pathway.
Chen X; Zhao W; Fan W
Oncol Rep; 2020 Jul; 44(1):349-359. PubMed ID: 32319657
[TBL] [Abstract][Full Text] [Related]
38. Single-cell transcriptomics reveals the regulative roles of cancer associated fibroblasts in tumor immune microenvironment of recurrent osteosarcoma.
Huang X; Wang L; Guo H; Zhang W; Shao Z
Theranostics; 2022; 12(13):5877-5887. PubMed ID: 35966586
[No Abstract] [Full Text] [Related]
39. Immunotherapy for osteosarcoma: Where do we go from here?
Wedekind MF; Wagner LM; Cripe TP
Pediatr Blood Cancer; 2018 Sep; 65(9):e27227. PubMed ID: 29923370
[TBL] [Abstract][Full Text] [Related]
40. Reprograming the tumor immunologic microenvironment using neoadjuvant chemotherapy in osteosarcoma.
Deng C; Xu Y; Fu J; Zhu X; Chen H; Xu H; Wang G; Song Y; Song G; Lu J; Liu R; Tang Q; Huang W; Wang J
Cancer Sci; 2020 Jun; 111(6):1899-1909. PubMed ID: 32232912
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
